Vertex Pharmaceuticals Announces Initiation of Pivotal Phase 2b/3 Trial for Povetacicept in Primary Membranous Nephropathy and Advances Biologics License Application for IgA Nephropathy
Reuters
Yesterday
Vertex Pharmaceuticals Announces Initiation of Pivotal Phase 2b/3 Trial for Povetacicept in Primary Membranous Nephropathy and Advances Biologics License Application for IgA Nephropathy
Vertex Pharmaceuticals Incorporated has announced progress in its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic targeting BAFF and APRIL cytokines. Pove is currently in pivotal trials for IgA nephropathy (IgAN) and primary membranous nephropathy (pMN), with the company highlighting its potential as a best-in-class therapy for multiple B cell-mediated kidney diseases. Vertex will present updated data from these trials, including results from more patients with longer duration of follow-up, at the American Society of Nephrology (ASN) Kidney Week 2025, scheduled for November 6-9 in Houston. Additionally, Vertex will host an investor event on November 8, 2025, to discuss the updated clinical data and other developments in its kidney disease portfolio. The presentation and Q&A will be accessible via webcast through the company's investor relations website.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vertex Pharmaceuticals Incorporated published the original content used to generate this news brief via Business Wire (Ref. ID: 20251016045727) on October 17, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.